Histone Modifications Drive Aberrant Notch3 Expression/Activity and Growth in T-ALL by Tottone, Luca et al.
ORIGINAL RESEARCH
published: 03 April 2019
doi: 10.3389/fonc.2019.00198
Frontiers in Oncology | www.frontiersin.org 1 April 2019 | Volume 9 | Article 198
Edited by:
Geoffrey Brown,
University of Birmingham,
United Kingdom
Reviewed by:
Ken Mills,
Queen’s University Belfast,
United Kingdom
Ewa Teresa Marcinkowska,
University of Wrocław, Poland
Michael Danilenko,
Ben-Gurion University of the Negev,
Israel
*Correspondence:
Isabella Screpanti
isabella.screpanti@uniroma1.it.
Rocco Palermo
rocco.palermo@uniroma1.it.
†Present Address:
Luca Tottone,
Rutgers Cancer Institute of New
Jersey, Rutgers University,
New Brunswick, NJ, United States
Nadezda Zhdanovskaya,
Department of Physics, Sapienza
University of Rome, Rome, Italy
Fabrizio Simeoni,
Cancer Research UK Manchester
Institute, The University of Manchester,
Manchester, United Kingdom
‡These authors have contributed
equally to this work and are joint first
authors
Specialty section:
This article was submitted to
Molecular and Cellular Oncology,
a section of the journal
Frontiers in Oncology
Received: 02 January 2019
Accepted: 08 March 2019
Published: 03 April 2019
Citation:
Tottone L, Zhdanovskaya N,
Carmona Pestaña Á, Zampieri M,
Simeoni F, Lazzari S, Ruocco V,
Pelullo M, Caiafa P, Felli MP,
Checquolo S, Bellavia D, Talora C,
Screpanti I and Palermo R (2019)
Histone Modifications Drive Aberrant
Notch3 Expression/Activity and
Growth in T-ALL. Front. Oncol. 9:198.
doi: 10.3389/fonc.2019.00198
Histone Modifications Drive Aberrant
Notch3 Expression/Activity and
Growth in T-ALL
Luca Tottone 1†‡, Nadezda Zhdanovskaya 1†‡, Álvaro Carmona Pestaña 1,
Michele Zampieri 2, Fabrizio Simeoni 1†, Sara Lazzari 1, Valeria Ruocco 1, Maria Pelullo 3,
Paola Caiafa 2, Maria Pia Felli 4, Saula Checquolo 5, Diana Bellavia 1, Claudio Talora 1,
Isabella Screpanti 1* and Rocco Palermo 1*
1Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy, 2Department of Cellular Biotechnologies and
Hematology, Sapienza University of Rome, Rome, Italy, 3Center for Life Nano Science@Sapienza, Istituto Italiano di
Tecnologia, Rome, Italy, 4Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy, 5Department of
Medico-Surgical Sciences and Biotechnology, Sapienza University of Rome, Latina, Italy
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive blood cancer caused
by the deregulation of key T-cell developmental pathways, including Notch signaling.
Aberrant Notch signaling in T-ALL occurs by NOTCH1 gain-of-function mutations
and by NOTCH3 overexpression. Although NOTCH3 is assumed as a Notch1 target,
machinery driving its transcription in T-ALL is undefined in leukemia subsets lacking
Notch1 activation. Here, we found that the binding of the intracellular Notch3 domain,
as well as of the activated Notch1 fragment, to the NOTCH3 gene locus led to
the recruitment of the H3K27 modifiers JMJD3 and p300, and it was required to
preserve transcriptional permissive/active H3K27 marks and to sustain NOTCH3 gene
expression levels. Consistently, pharmacological inhibition of JMJD3 by GSKJ4 treatment
or of p300 by A-485 decreased the levels of expression of NOTCH3, NOTCH1 and
of the Notch target genes DELTEX1 and c-Myc and abrogated cell viability in both
Notch1- and Notch3-dependent T-cell contexts. Notably, re-introduction of exogenous
Notch1, Notch3 as well as c-Myc partially rescued cells from anti-growth effects induced
by either treatment. Overall our findings indicate JMJD3 and p300 as general Notch1
and Notch3 signaling co-activators in T-ALL and suggest further investigation on the
potential therapeutic anti-leukemic efficacy of their enzymatic inhibition in Notch/c-Myc
axis-related cancers and diseases.
Keywords: Notch signaling, T-cell lymphoblastic leukemia, epigenetics, JMJD3, p300, gene regulation, GSKJ4,
A-485
INTRODUCTION
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy caused by
abnormal activity of signaling pathways regulating key stages of intrathymic lymphopoiesis. Notch
signaling is an evolutionary conserved developmental pathway based on the interaction between
different Notch receptors (Notch1-4) and specific ligands. The binding of a ligand allows two
sequential proteolytic cleavages of the Notch receptor, mediated by ADAM metalloproteases and
gamma-secretase complex, which release the intracellular active domain of Notch (NICD) from
the cell membrane. Soluble NICD translocates to the nuclear compartment where it assembles a
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multifactorial complex to elicit its transcriptional activity
(1). Among the members of Notch receptors family, proper
functioning of Notch1 and Notch3 signaling is critical during
physiological T cell-lineage intra-thymic development (2), and
their aberrant activities perturb thymocyte differentiation and
drive T-ALL pathogenesis by promoting a distinct oncogenic
transcriptional program (3–10).
Notch1 signaling hyper-activation is sustained in about 60%
of T-ALL patients by gain-of-function mutations occurring in
NOTCH1 gene, which promote increased stability and ligand-
independent release of the N1ICD (4). Notch3 receptor has
been found overexpressed in most of the patients analyzed
(3), and in primary samples, unlike Notch1, its activation was
preferentially associated with high expression of full-length
receptor rather than with gene mutations or rearrangements
(9). These findings are in line with evidence demonstrating
that Notch3 receptor is more susceptible than Notch1 to
spontaneous basal transcriptional activity due to ligand-
independent proteolysis, even though both receptors elicit
comparable levels of ligand-dependent activities (11). Overall,
these observations indicate machinery regulatingNOTCH3 over-
expression among the major causes of its oncogenic malfunction
in this malignancy. However, molecular mechanisms sustaining
NOTCH3 expression remain mostly undefined and, although it is
assumed that NOTCH3 is a target gene of Notch1, to date it has
not been clarified how its oncogenic expression/activation results
to be aberrant even in T-ALL cases lacking Notch1 activation.
Notably, recent studies indicated epigenetic modifications
at NOTCH3 gene locus to drive its expression in leukemia,
as it has been demonstrated to be hypermethylated in B-ALL
samples not expressing NOTCH3, while it has been found
poorly or unmethylated in T-ALL context (12). Besides, we
previously demonstrated that the binding of BORIS/CTCFL
at NOTCH3 proximal promoter is critical to maintain active
histone H3 tri-methylated lysine 4 chromatin mark (H3K4me3)
(13). Other studies indicated the intron1 of NOTCH3 as an
enhancer region devoid of repressive H3 tri-methylated lysine
27 mark (H3K27me3) and associated with the active chromatin
mark histone H3 acetylated lysine 27 (H3K27ac) in T-ALL cells,
This gene region appears to be required for Notch1-dependent
transcriptional activation of NOTCH3 (14, 15).
Levels of H3K27me3 mark at gene loci result from the
balance between the methyltransferase activity of the Polycomb-
Repressive Complex 2 (PRC2) component EZH2 (16) and
Abbreviations: T-ALL, T-cell acute lymphoblastic leukemia; ADAM, a
disintegrin and metalloproteinase; NICD, Notch intracellular domain; N1ICD,
Notch1 intracellular domain; B-ALL, B-cell Acute Lymphoblastic Leukemia;
BORIS/CTCFL; H3K4me3, histone H3 lysine 4 tri-methylated; H3K27me3,
histone H3 lysine 27 tri-methylated; H3K27ac, histone H3 lysine 27 acetylated;
H3K27, histone H3 lysine 27; PRC2, polycomb repressive complex 2; EZH2,
Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit; JMJD3,
Jumonji Domain-Containing Protein 3; UTX, Ubiquitously-Transcribed X
Chromosome Tetratricopeptide Repeat Protein; NURD, Nucleosome Remodeling
and Deacetylase; HDAC1, Histone Deacetylase 1; HDAC2, Histone Deacetylase
2; GFP, Green Fluorescent Protein; N3ICD, Notch3 intracellular domain; TSS,
transcriptional start site; GSI, gamma-secretase inhibitor; CSL, CBF-1/SuH/Lag-1;
RBPjk, recombination signal binding protein for immunoglobulin Kappa J Region;
PARP, Poly(ADP-Ribose) Polymerase.
of the enzymatic activity of the H3K27 demethylases JMJD3
(also referred to as KDM6B) and UTX (also referred to as
KDM6A) (17). Recently, H3K27me3 modifiers have been linked
to T-ALL onset and progression and have been demonstrated
to be involved in transcriptional crosstalk with Notch1.
Indeed, about 25% of T-ALL patients harbor loss-of-function-
mutation or deletion of EZH2, or of its cofactor SUZ12 (18).
Consistently, EZH2 acts as a tumor suppressor in T-ALL
by antagonizing Notch signaling transcriptional activity (18).
Similarly, inactivating gene lesions of UTX characterize a group
of T-ALL patients and it has been shown that deletion of UTX
accelerates leukemia growth in Notch1-dependent mice models
(19, 20). Nevertheless, a more recent study proposed that UTX
might act as a proto-oncogene in distinct subgroups of T-ALL
characterized by the expression of the oncogenic transcription
factor TAL1 (21). On the other hand, the H3K27 de-methylase
JMJD3 has been found overexpressed in T-ALL samples when
compared with physiological T-cell subsets, and it has been
shown to sustain Notch1 oncogenic transcriptional program in
murine models of T-ALL (19). In general, levels of H3K27ac
mainly result from the balance between the enzymatic activity of
the acetyltransferase p300 and of the Nucleosome Remodeling
Deacetylase complex (NURD) subunits HDAC1 and HDAC2
(22). It is well accepted that p300 acts as a Notch1 transcriptional
co-activator (23, 24).
Here, we further explored the interplay between Notch
signaling and the above-mentioned chromatin modifiers to
gain further insights into molecular mechanisms driving
aberrant expression and activation of Notch3 receptor in T-
ALL even in contexts lacking Notch1 activation, with the aim
to reveal novel potential therapeutic targets relevant in this
hematological cancer.
MATERIALS AND METHODS
Cell Lines and Treatments
MOLT3, DND41, KOPTK1, P12/Ichikawa and TALL-1 cells
were maintained in RPMI-1640 (31870025; Gibco, Carlsbad,
CA, USA) containing 10% fetal bovine serum (FBS) (10270106;
Gibco). HEK cells and HEK cells stably expressing full-length
human Jagged1 were cultured in D-MEM (11960044; Gibco)
containing 10% FBS (10270106; Gibco). To inhibit Notch S3
cleavage, MOLT3 and TALL-1 cells were treated with 10µM
gamma-secretase-inhibitor IX (DAPT) (565770; Calbiochem,
Darmstadt, Germany) or with vehicle (DMSO) (D8418; Sigma-
Aldrich, St Louis, MO, USA) for 48 h. For DAPT wash-
out experiment, after 48 h of 10µM DAPT treatments, cells
were washed twice and cultured for 6 h in fresh medium
without DAPT and in presence of 20µg/ml of Cycloheximide
(C4859; Sigma-Aldrich) (post DAPT). To block Notch signaling,
P12/Ichikawa cells were cultured inmedium containing 10µg/ml
of blocking anti-human Notch1 clone MHN1-519 (352104;
Biolegend, San Diego, CA, USA) for 48 h, as previously
described (25). Mouse IgG1 (40140; Biolegend) was used as
isotype control.
To trigger Notch1 signaling, 6 × 106 TALL-1 cells were
co-cultured on a monolayer of Jagged1-expressing HEK cells
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(H-J1) or HEK cells as control (H) for 48 h. Suspension cells
were recovered, washed in phosphate-buffered saline (PBS) and
subjected to further analysis. To inhibit enzymatic activity of
JMJD3 or of p300, cells were exposed to 2µM GSK J4 HCL
(GSKJ4) (S7070; Selleckchem, Houston, TX, USA) or to 5µM
A-485 (HY-107455; MedChemExpress,Monmouth Junction, NJ,
USA) for times indicated in figures.
Protein and Histones Extracts Preparation,
Western Blot, and Antibodies
To obtain total protein extracts, cells were lysed in Laemmli
buffer (2X Laemmli Sample Buffer (1610737; Biorad, Hercules,
CA) by sonication and clarified at 10.000 × g for 10min. Before
immunoblotting, samples were added with β-mercaptoethanol
(M6250; Sigma-Aldrich) and boiled for 10min. To analyze
histone mark levels, histones were extracted by using the
acid extraction protocol by Abcam (Cambridge, UK). For
immunoblotting, protein and histone extracts were run on SDS-
polyacrylamide gels and transferred to nitrocellulose membranes
(1620115; Biorad). Blots were incubated with antibodies against:
Notch1Val1744 (4147; Cell Signaling Technology, Beverly,
MA, USA), Notch1 D1E11 (3608; Cell Signaling Tecnology),
Notch3 (2889; Cell Signaling Technology), H3K27me3 (9733;
Cell Signaling Technology), H3K27ac (4353; Cell Signaling
Technology), H3 (07-690; Merck Millipore, Darmstadt,
Germany), PARP (9542; Cell Signaling Technology), p27 (3688;
Cell Signaling Technology), β-actin (A5441; Sigma-Aldrich),
Myc Tag (06-549; Sigma-Aldrich), HA (16B12; Covance Inc,
Princeton, NJ, USA) followed by hybridization with Antibodies
HRP conjugated: anti-rabbit (A120-108P; Bethyl Laboratories,
TX, USA) or anti-mouse (A90-116P; Bethyl Laboratories).
For Chip experiments following antibodies were used: Notch3
(2889; Cell Signaling Technology), Notch1 (3608; Cell Signaling
Technology), H3K27me3 (07-473; Merck Millipore, Darmstadt,
Germany), H3K27ac (4353; Cell Signaling Technology),
H3K4me3 (07-473; Merck Millipore), JMJD3 (ab38113; Abcam,
Cambridge, UK), p300 (sc-584, Santa Cruz Biotechnology,
Santa Cruz, CA, USA), normal rabbit IgG (sc-2027; Santa
Cruz Biotechnology) and normal mouse IgG (sc-2025; Santa
Cruz Biotechnology).
RT-PCR Analysis
Total RNA was isolated by using TRIZOL reagent (15596018;
Invitrogen, Carlsbad, CA, USA) as described previously (26).
cDNA was synthetized by using High Capacity cDNA Reverse
Transcription Kit (4368814; Applied Biosystems, Foster City,
CA, USA) according to the manufacturer’s protocol. Taqman
Gene Expression Master Mix (4304437) and Taqman Gene
Expression Assays for NOTCH1 (Hs01062014_m1), NOTCH3
(Hs00166432_m1), DELTEX1 (Hs01092201_m1), GAPDH
(Hs02758991_g1), and 18S (4352930E) were purchased from
Applied Biosystems. Relative quantification was carried out
using the comparative 11CT method, as previously described
(27). GAPDH or 18S were used to normalize mRNA levels.
Measurements were performed in technical triplicates and
figures show the averages± SEM of at least 3 biological replicates.
Chromatin Immunoprecipitation (ChIP)
To crosslink protein/DNA complex, cells were incubated for
10min at 37◦C after the addition of 1% formaldehyde (47608;
Sigma-Aldrich) to the media. Crosslinking was quenched by
the addition of 0.125M glycine (50046; Sigma-Aldrich) to the
media followed by 10min of incubation at RT. Cells were washed
twice with PBS containing protease inhibitors (S8820; Sigma-
Aldrich) and then lysed in Triton Buffer (0,25% Triton X-100,
1mM EDTA, 0,5mM EGTA, 10mM Tris-HCl, pH 8) containing
protease inhibitors (S8820; Sigma-Aldrich) for 10min in ice.
Nuclei were lysed in Lysis Buffer (0.5% SDS, 5mMEDTA, 50mM
Tris-HCl, pH 8) containing protease inhibitors (S8820; Sigma-
Aldrich) for 10min in ice and sonicated for 10min (30 s on, 30 s
off) by using Bioruptor (Diagenode, Liege, Belgium). Samples
were centrifuged at max speed to remove debris and then diluted
by adding 9 volumes of Dilution Buffer (0.01% SDS, 1% Triton
X-100, 1.2mMEDTA pH 8.0, 16.7mMTris-HCl pH 8.0, 167mM
NaCl) containing protease inhibitors (S8820; Sigma-Aldrich) and
pre-cleared for 1 h at 4◦C with 1% v/v of Protein A/G PLUS-
Agarose (sc-2003, Santa Cruz Biotechnology). Ten percent of
sample was then kept out as input, and the remaining sample
was split into tubes and processed by immunoprecipitation.
Four micrograms of each antibody or of the appropriate normal
control IgG were added to each tube and incubated overnight
in rotation at 4◦C. Antibody–protein–DNA complexes were
collected by adding to the samples 10% v/v of salmon sperm
DNA/Protein A agarose (#16-157, Merck Millipore, Darmstadt,
Germany) or salmon sperm DNA/Protein G agarose (16-201;
Merck Millipore, Darmstadt, Germany). After 1 h of incubation,
agarose pellets were washed consecutively in LSW Buffer (0.1%
SDS, 1% Triton X-100, 2mM EDTA, 10mM Tris-HCl, pH 8,
150mM NaCl), HSW Buffer (0.1% SDS, 1% Triton X-100, mM
EDTA, 20mM Tris-HCl, pH 8, 500mM NaCl), LiCl Buffer
(0.25M LiCl, 1% NP-40, 1% deoxycholic acid sodium salt, 1mM
EDTA, 10mM Tris-HCl, pH 8), and in TE Buffer (10mM
Tris-HCl pH 8.0, 1mM EDTA). DNA-protein complexes were
eluted by adding Elution Buffer (1% SDS, 10mM Tris-HCl pH
8,5mM EDTA) to samples, including Input samples, followed by
15min of shaking at 1,000 RPM at 65◦C. Elution procedure was
repeated two time, and followed by treatment with proteinase K
(P2308; Sigma-Aldrich). Protein-DNA crosslinks were reversed
at 65◦C overnight. DNA was extracted by Phenol/Chloroform,
precipitated by using ethanol and glycogen, air-dried, and re-
suspended in H2O. Relative NOTCH3 fragment enrichments
were determined by subsequent SYBR green qPCR by using
the following primers previously described (14): Forward
N3 INTRON1: GTCTCAGCACACCCCATTCT; Reverse N3
INTRON1: AACCACAAAGCAGGGGAAG; Forward N3 UP-
TSS: TGGCCTCAGTTTCCAGAGTT; Reverse N3 UP-TSS:
CACACCCAACCTCGTGAAC. PCR reactions were run at 95◦C
for 10min, followed by 40 cycles at 95◦C for 15 s and 60◦C for 30 s
and was performed using the ViiATM 7 Real-Time PCR System
detection system (Applied Biosystems, Foster City, CA, USA).
Values were normalized to input DNA by using the % input
method. Measurements were performed in technical triplicates
and figures show the averages ± SEM of the measurements
obtained from two biological replicates.
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Plasmids and Transfections
To generate a construct expressing GFP-fused constitutively
active human Notch3 intracellular domain (hICN3), the human
N3ICD fragment was amplified by using primers FW 5′-
GTCATGGTGGCCCGG-3′ and REV 5′-CCAACACTTGCC
TCTTGGG-3′, and cloned into themammalian expression vector
pcDNATM3.1/CT-GFP TOPO according to the manufacturer’s
instructions (K4820-01, Invitrogen). The expression vector
PIRVNeoSV containing the human c-Myc cDNA coding
sequence (c-Myc) was kindly provided by Dr. Giuseppe
Giannini (Sapienza University, Rome, Italy). pCMV3-HA vector
containing the human EZH2 coding sequence (HA-EZH2) was
purchased from Sino Biological (HG11337-CY; Sino Biological,
Beijing, China).
Transient transfections with expression vectors or with the
relative control plasmids were carried out by using Neon
Transfection System (MPK5000; Invitrogen) as described by the
manufacturer. Following 24 h of transfection of hICN3 plasmid
and the relative control plasmid in DND41, about 40–50% of
transfection efficiency was detected by fluorescence microscopy.
The strength of HA-EZH2, hICN3, and c-Myc transfection
was confirmed by western blotting shown in Figures 4B,
6B,C, respectively.
Cell Viability Assay
Human T-ALL cell lines were seeded in 96-well plate at 5
× 105 cells/ml and treated with 2µM GSKJ4 or 5µM A-
485 for times indicated in figures. As control samples, cells
were treated with equal volumes of the vehicle (DMSO).
Cell viabilities were assayed by using the MTS-based assay
CellTiter 96 R© AQueous One Solution Cell Proliferation Assay
(G3580; Promega, Madison, WI, USA), as previously described
(28). Absorbances were measured at 490nm by using GloMax
Multidetection System (Promega). Data were collected as units of
absorbance (ABS) and normalized to cell proliferation percentage
by following equation: % Cell Viability = (ABScells+compound –
ABSmedium+compound) / (ABScells+DMSO – ABSmedium+DMSO) X
100. Measurements were performed in technical duplicates or
triplicates and figures show the averages ± SEM of at least 3
biological replicates.
Trypan blue (T8154, Sigma-Aldrich) was used to count viable
and dead cells.
Rescue Assays
Growth sensitivity to treatment with 2µM GSKJ4 or with
5µM A-485 was compared between DND41 cells transduced
with retroviral construct encoding the entire murine Notch1
intracellular fragment CMMP-ICN1-IRES-EGFP (mICN1)
and the empty relative control vector CMMP-IRES-EGFP
(empty) [previously described (29)], and between DND41 cells
transiently transfected with hICN3 expression plasmid and the
relative control plasmid, and between TALL-1 cells transiently
transfected with the expression vector c-Myc and the cell
counterparts transfected with the empty control vector. Trypan
blue (T8154, Sigma-Aldrich) was used to count viable cells.
Statistical Analysis
All statistical tests were carried out by using GraphPad Prism
version 6.0 (GraphPad Software, San Diego California, USA).
Statistical analysis of data between two groups was carried out
by two-tailed Student’s unpaired t-test. Multiple comparisons
analysis was carried out by one-way ANOVA followed by
Tukey’s post-hoc test. Differences were considered significant
when P-values< 0.05. Values significance: ∗P< 0.05, ∗∗P< 0.01,
∗∗∗P < 0.001, ∗∗∗∗P < 0.0001.
RESULTS
NOTCH3 Is a Direct Target of Both Notch1
and Notch3 Signaling
Previous findings indicating NOTCH3 as a transcriptional
Notch1 target gene in T-ALL (5, 6, 14, 30, 31) have been further
validated here as the consequence of Notch1 signaling inhibition.
Pharmacological Notch1-blockade by gamma-secretase inhibitor
DAPT (DAPT) in MOLT3 cells harboring Notch1 gain-of-
function mutation resulted in almost complete clearance of
the active N1ICD (N1VAL) and in strong down-regulation
of the mRNA levels of NOTCH3 and of Notch target
gene DELTEX1, that were recovered by subsequent Notch1
signaling reactivation following DAPT removal treatment (post
DAPT) (Figure 1A). Likewise, the exposure to Notch1-blocking
antibody (ABN1) prevented Notch1 activation and abrogated
NOTCH3 and DELTEX1 expression in P12-ICHIKAWA cells
(referred to as P12 cells) displaying constitutive Notch1 activity
(Figure 1B). Notably, also NOTCH1 gene expression was slightly
affected (Figure 1B).
To investigate whether NOTCH3 transcriptional control
by Notch1 could be functionally related to specific cell
contexts, we analyzed modulation of NOTCH3 gene expression
in response to Notch1 on/off assay in TALL-1 cells that
express the full-length form of Notch1 receptor lacking ligand-
independent signaling activation (9). For this purpose, TALL-
1 cells have been co-cultured on a mono-layer of Human
embryonic kidney (HEK) cells ectopically expressing the Notch-
ligand Jagged1 (H-J1) in the absence or presence of ABN1.
The co-culture induced Notch1 activation in TALL-1 cells
that was accompanied by increased NOTCH3 and DELTEX1
expression when compared with the TALL-1 cell co-cultured
on the wild type HEK cells (H) (Figure 1C). Conversely, the
addition of Notch1-blocking antibody (H-J1 ABN1) prevented
Notch1 activation and abrogated NOTCH3 and DELTEX1
expression (Figure 1C).
Previously reported chromatin immunoprecipitation (ChIP)
assays in Notch1-dependent SupT1 and CUTLL1 human T-
ALL cell lines revealed Notch1 binding to the NOTCH3 intron1
and indicated this region as a Notch1-responsive element in
NOTCH3 gene (14, 15). Consistently, our in-silico analysis
by Genomatix MatInspector and by UCSC Genome Browser
covering 4 kb surrounding the human NOTCH3 transcriptional
start site (TSS) revealed a CSL/RBPjk binding site at 3,174 bp
downstream the TSS highly conserved in primates and rodents
(Figure 1D). No potential CSL/RBPjk consensus sequences have
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FIGURE 1 | NOTCH3 is a direct target of Notch3 and Notch1 in T-ALL. Relative NOTCH1, NOTCH3, and DELTEX1 gene expression (upper panels) and protein levels
of endogenous Notch1 active domain (N1VAL) and β-actin (lower panels) in: (A) MOLT3 cells treated for 48 h with 10µM DAPT (DAPT) or with DMSO and, after
washing, incubated for further 6 h in fresh medium without DAPT and in presence of 20µg/ml of Cycloheximide (post DAPT), (B) P12 T-ALL cells exposed for 48 h
(Continued)
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FIGURE 1 | to anti-human blocking Notch1 antibody (ABN1) or to the isotype controls (IgG), and (C) TALL-1 cells co-cultured for 48 h on a monolayer of HEK cells
expressing Jagged1 (H-J1) or on the not expressing Jagged1 cell counterpart (H) and treated with anti-human Notch1 blocking antibody (H-J1 ABN1) or with the
isotype control (H-J1 IgG). Data represent mean values of three or four biological replicates ± Standard Error of the Mean (S.E.M.); (n = 3 or 4) *P < 0.05, **P < 0.01,
***P < 0.001. (D) UCSC Genome Browser Screenshot showing the conserved CSL/RBPjk binding site predicted by Genomatix Maltinspector at the NOTCH3 intron1
(upper panel); a schematic representation of the human NOTCH3 genomic region within 5′-upstream (UP-TSS) and the intron1 (INTRON1) regions showing DNA
fragments amplified by PCR primers following the Chip procedures. Amplicons are indicated in green at the UP-TSS and in red at the INTRON1. Predicted TSS has
been fixed as +1 bp. CSL/RBPjk (CSL) consensus site is indicated by the yellow box (lower panel). (E) Cross-linked chromatin derived from TALL-1 cells co-cultured
for 48 h on a monolayer of H-J1 cells or on the H cell counterpart was immunoprecipitated with an antibody against the C-terminal domain of Notch1 (N1ICD) or with
the isotype control (IgG) and analyzed by qPCR. The schematic position of the amplicons is shown up the charts. Data are expressed as a percentage of input and
represent mean values for two biological replicates ± Standard Error of the Mean (S.E.M.); (n = 2). (F) Relative NOTCH1, NOTCH3, and DELTEX1 gene expression
(upper panel) and protein levels of endogenous Notch3 intracellular domain (N3ICD) and β-actin (lower panel) in TALL-1 cells treated for 48 h with 10µM DAPT (DAPT)
or with DMSO and, after washing, incubated for further 6 h in fresh medium without DAPT and in presence of 20µg/ml of cycloheximide (post DAPT). Data represent
mean values of three biological replicates ± Standard Error of the Mean (S.E.M.); (n = 3) *P < 0.05, **P < 0.01, ***P < 0.001. (G) Cross-linked protein-DNA
complexes from TALL-1 cells treated with 10µM DAPT or DMSO for 48 h were subjected to immunoprecipitation with an antibody against the C-terminal domain of
Notch3 (N3ICD) or with the relative isotype control (IgG) and subjected to qPCR analysis. Schematic positions of the amplicons are shown up the charts. ChIP results
are presented as the percentage of the input DNA. Data represent mean values of two biological replicates ± Standard Error of the Mean (S.E.M.); (n = 2). Uncropped
western blots related to this figure are displayed in Supplementary Figure 1.
been found upstream the TSS. To further support NOTCH3 as
a direct Notch1 target and to evaluate the context-dependency
of this regulation, we analyzed by CHIP assays the endogenous
binding of N1ICD to the above described NOTCH3 intron1
fragment (N3 INTRON1) and to a region proximal to the TSS
(N3 UP-TSS) in TALL-1 cells following the ligand-dependent
activation of the signaling (The position of PCR amplicons is
described in Figure 1D, lower panel). As expected, in TALL-1 co-
cultured onH-J1 cells, N1ICDwas bound to N3 INTRON1, while
no signal was detected in the immunoprecipitated chromatin
from TALL-1 co-cultured on control HEK cells (H) (Figure 1E).
In contrast, N3 UP-TSS region, not containing CSL/RBPjk,
showed no amplification and served as a negative control of
the Chip assays (Figure 1E). These data confirmed NOTCH3
as a downstream Notch1 target gene. However, they still left
open the question of how its high transcription could be
sustained in Notch1-defective T-ALL patients and in TALL-
1 cells where Notch3 is the only source of active Notch
signaling (9). Interestingly, the exposure of TALL-1 cells to DAPT
treatment reduced basal expression of NOTCH3 and DELTEX1,
which was recovered after Notch3 receptor reactivation following
DAPT removal (post DAPT) (Figure 1F). Therefore, we asked
whether Notch3 could sustain its own expression by directly
interacting with its gene locus. Similarly to our observations
on N1ICD, we detected high levels of N3ICD enrichment at
the N3 INTRON1 in TALL-1 cells, whereas its binding was
absent at the UP-TSS region (Figure 1G). Furthermore, N3ICD
occupancy at the intronic fragment was greatly reduced by DAPT
treatment (Figure 1G).
Interestingly, while no significant variation in NOTCH1
expression was observed in the above-mentioned Notch1 on/off
assays (Figures 1A,C), except for a slight downregulation
following Notch1 inhibition in P12 cells (Figure 1B),
modulation of Notch3 activity resulted in changes of
expression levels of NOTCH1 mRNA in TALL-1 cells
(Figure 1F). This suggested that Notch1 and Notch3 could
reciprocally sustain their expression in T-ALL and that exclusive
Notch3 on-state could promote its own gene expression in
TALL-1 cells.
Notch3 and Notch1 Preserve Active H3K27
Modifications at NOTCH3 Gene Locus
We and others have previously suggested that epigenetic
regulation at NOTCH3 gene locus promotes its aberrant
gene expression in some cancers, including leukemia (12–
14). Interestingly, it has been shown that Notch1 sustains the
expression of HES1 and DELTEX1 by antagonizing the binding
of PRC2/EZH2 complex and by recruiting JMJD3 on their
regulatory regions, therefore promoting loss of H3K27me3 (18,
19). In addition to H3K27me3modulation, it is well-documented
that dynamic changes in Notch1 or Notch3 signaling activity
result in the rapid variation of H3K27ac status across the
enhancer regions of several Notch responsive genes (10, 15).
Therefore, we speculated that similar epigenetic machinery
might cooperate with Notch signaling in coordinating NOTCH3
transcription in T-ALL. To evaluate this hypothesis, we analyzed
the effects of Notch inhibition on the enrichment of both
active H3K27ac and repressive H3K27me3 epigenetic marks and
on the occupancy by the related histone-modifying factors at
the NOTCH3 gene in Notch3-dependent TALL-1 and Notch1-
dependent MOLT3 T-ALL cells.
ChIP experiments unveiled that in TALL-1 cells the binding
of N3ICD at the N3 INTRON1 was strictly associated with
the gain of H3K27ac and loss of H3K27me3 (Figure 2A),
which was consistent with the parallel co-recruitment of the
histone modifiers p300 and JMJD3 (Figure 2A). Interestingly,
subsequent Notch3 inhibition by DAPT completely reversed the
H3K27 epigenetic marks at the NOTCH3 locus. Indeed, DAPT
treatment resulted in H3K27me3 enrichment and H3K27ac
loss and promoted the eviction of both p300 and JMJD3
from the N3 INTRON1 (Figure 2A). Of note, no binding of
p300 or JMJD3 has been detected at the UP-TSS fragment
(Figure 2B). In line with previous evidence showing dynamic
changes in histone H3K4me3 status occurring at Notch target
genes following Notch signaling modulations (33, 34), we
observed high levels of H3K4me3 bound at both regulatory
regions of NOTCH3 gene in TALL-1 cells, which declined upon
Notch3 blockade by DAPT treatment (Figure 2B). Recently,
Choi and colleagues demonstrated that Notch1 and Notch3 drive
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FIGURE 2 | Notch3 preserves active H3K27 modification status on its gene locus. Cross-linked protein-DNA complexes from TALL-1 cells treated with 10µM DAPT
or DMSO for 48 h were subjected to immunoprecipitation with antibodies against: (A) H3K27ac, H3K27me3, p300, JMJD3, (B) p300, JMJD3, H3K4me3,
(Continued)
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FIGURE 2 | and analyzed by qPCR. Immunoprecipitations against relative isotypes (IgG) were performed in parallel. Schematics position of the amplicons is shown up
the charts. ChIP results are presented as the percentage of the input DNA. Data represent mean values of two biological replicates ± Standard Error of the Mean
(S.E.M.); (n = 2). (C) ChIP-seq tracks of Notch3 and H3K27ac dynamic peaks visualized by IGV (32) surrounding the NOTCH3 locus derived from previously
described ChIP-seq data of human TALL-1 cells treated with gamma-secretase inhibitor (Notch OFF) or with vehicle alone (Notch ON) (GSE104262) (10).
a common oncogenic transcriptional program in T-ALL and that
most of the functional Notch3 binding sites in TALL-1 cells,
similarly to what was observed previously by Aster group for
Notch1 in CUTLL1 cells (15), are located in enhancer regions
associated with dynamic H3K27ac modulation (10). By analyzing
their raw data of ChIP-seq (NCBI’s Gene Expression Omnibus
database; GEO GSE104262), we confirmed the presence of the
above-described dynamic Notch3 binding sites located at the N3
INTRON1, which is strictly associated with change in H3K27ac
marks in response to Notch3 signaling modulations in TALL-1
cells (Figure 2C).
In line with the functional similarity between the two Notches,
we detected N1ICD constitutively associated to N3 INTRON1
(Figure 3A) in combination with high enrichment in H3K27ac,
p300, JMJD3, and H3K4me3 in Notch1-dependent MOLT3 cells
(Figures 3B,C). Similarly to TALL-1 cells, DAPT treatment of
MOLT3 cells depleted N1ICD, p300 and JMJD3 interaction,
dropped down H3K27ac and H3K4me3 levels (Figure 3) and
increased H3K27me3 occupancy at the NOTCH3 intronic region
(Figure 3B). Again, we observed high levels of H3K4me3
at the N3 UP-TSS while JMJD3 and p300 binding at this
region was detected neither in untreated nor in DAPT-treated
cells (Figure 3C).
Taken together, these data indicate that Notch3 and Notch1
promote the recruitment of JMJD3 and p300 to the NOTCH3
gene locus, which in turn preserves permissive local histone
H3K27 marks along with H3K4 trimethylation to sustain
gene expression.
GSKJ4 and A-485 Impair T-ALL Cells
Viability by Targeting Oncogenic
Notch/c-Myc Axis
To further assess whether JMJD3 and p300 are required for
NOTCH genes transcriptional activation and to study their
functional role in Notch-dependent T-ALL cell contexts, we
evaluated the effects of the inhibition of their enzymatic activities
on the expression of NOTCH3, NOTCH1 and most prominent
Notch target genes and on the proliferation rate in different T-
ALL cell lines. The inhibition of histone modifiers activity has
been achieved by treating for 48 h cells with the commercially
available specific inhibitors GSKJ4 for JMJD3 (19) or A-485 for
p300/CBP (35).
By this approach, we found that GSKJ4 treatment abrogated
the expression of NOTCH3 and NOTCH1 at both gene and
protein levels and reduced the transcription of Notch target
gene DELTEX1 in T-ALL cells (Figures 4A,C). Confirming the
bona fide of the treatment, we found that GSKJ4 exposure was
associated with increased H3K27me3 and decreased H3K27ac
global accumulation (Figures 4A,C, lower panels). Previous
evidence indicated that Notch1 activation antagonized the
binding of EZH2 (the JMJD3 enzymatic counterpart) on target
genes to allow the loss of H3K27me3 (18). Thus, we speculated
that in TALL-1 cells, harboring EZH2 missense mutations (20),
EZH2 loss of function might potentiate JMJD3 activity to
preserve an open chromatin conformation at the NOTCH3 gene
locus. Supporting this hypothesis, the ectopic expression of the
wild type form of EZH2 reduced the levels of NOTCH3 and
DELTEX1, while unexpectedly, it did not influence significantly
NOTCH1 expression in TALL-1 cells (Figure 4B).
Consistently with the above data showing that the binding
of p300 to the NOTCH3 enhancer positively combined with the
amount of the active chromatin H3K27ac and with NOTCH3
expression following Notch on/off state (Figures 2, 3), chemical
inhibition of p300/CBP by A-485 decreased NOTCH3 expression
levels (Figures 4D,E). As expected, also NOTCH1 and DELTEX1
levels were affected by p300/CBP inhibition in either Notch3-
dependent (Figure 4D) or Notch1-dependent cells (Figure 4E).
Notably, as previously shown in prostate cancer cells (35), A-
485 selectively suppressed global acetylation of H3K27, without
any significant alteration in global H3K27 tri-methylation status
in both Notch1 and Notch3 dependent T-cells (Figures 4D,E,
lower panels).
In line with their anti-Notch signaling activity, treatment with
low doses of either GSKJ4 or A-485 decreased the proportion
of viable cells, by increasing cell death and/or decreasing
the number of living cells in different T-ALL cell contexts
(Figures 5A,C and Supplementary Figure 5). Consistently, both
treatments reduced c-Myc expression and increased the levels
of both the anti-proliferative cyclin-dependent kinase inhibitor
p27KIP1 (p27) and the pro-apoptotic cleaved form of poly ADP-
ribose polymerase PARP (Figures 5B,D). To further evaluate
whether their biological effects occurred via Notch inhibition, we
compared the effects of 48 h of exposure to these drugs on cell
viability in DND41 cells transduced with retroviruses encoding
murine N1ICD (mICN1) and with the cellular counterparts
transduced with the empty retroviral vector (empty). As
expected, mICN1 expression partially rescued DND41 cells
from the viability inhibitory effects induced by both GSKJ4
and A-485 (Figure 6A, upper panel) and, interestingly, it
preserved N1ICD endogenous expression from the effects of
both drugs (Figure 6A, lower panel). Similarly, the reduction
in numbers of viable cells induced by 48 h of treatments with
GSKJ4 or A-485 in DND41 cells was in part prevented by
the exogenous reintroduction of the human N3ICD (hICN3)
(Figure 6B, upper panel) and the constitutive expression of
hICN3 shielded Notch3 endogenous expression (Figure 6B,
lower panel).
Since either GSKJ4 or A-485 treatment decreased c-Myc levels
in T-ALL cells (Figures 5B,D), we reasoned that the axis between
Notch signaling and c-Myc could be a critical target of these drugs
and that c-Myc inhibition might be required for their biological
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FIGURE 3 | Notch1 sustains active H3K27 modification status on NOTCH3 gene locus. Cross-linked protein-DNA complexes from MOLT3 cells treated with 10µM
DAPT or DMSO for 48 h were subjected to immunoprecipitation with antibodies against: (A) the C-terminal domain of Notch1 (N1ICD), (B) H3K27ac, H3K27me3,
p300, and JMJD3, (C) p300, JMJD3 and H3K4me3, and analyzed by qPCR. Immunoprecipitation against relative isotypes (IgG) were performed in parallel.
Schematics positions of the amplicons are shown up the charts. ChIP results are presented as the percentage of the input DNA. Data represent mean values of two
biological replicates ± Standard Error of the Mean (S.E.M.); (n = 2).
Frontiers in Oncology | www.frontiersin.org 9 April 2019 | Volume 9 | Article 198
Tottone et al. Histone Modifications Regulate Notch Signaling
FIGURE 4 | GSKJ4 and A-485 treatments modulate Notch receptors expression and activity. Relative NOTCH1, NOTCH3, and DELTEX1 gene expression (upper
panels) and N1ICD, N3ICD, β-actin, H3K27me3, H3K27ac, and H3 total expression levels (lower panels) in: (A) TALL-1 or (C) MOLT3 cells treated for 48 h with 2µM
GSKJ4 or with DMSO. (B) Relative NOTCH1, NOTCH3, and DELTEX1 gene expression (upper panel) and HA and β-actin protein levels (lower panel) in TALL-1
(Continued)
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FIGURE 4 | cells transfected with HA-tagged EZH2 expression vector (HA-EZH2) or with the empty control vector. Relative NOTCH1, NOTCH3, and DELTEX1 gene
expression (upper panels) and N1ICD, N3ICD, β-actin, H3K27me3, H3K27ac, and H3 total expression levels (lower panels) in: (D) TALL-1 or (E) MOLT3 cells treated
for 48 h with 5µM A-485 or DMSO. Data represent mean values of three biological replicates ± Standard Error of the Mean (S.E.M.); (n = 3) *P < 0.05, **P < 0.01,
***P < 0.001. Uncropped western blots related to this figure are displayed in Supplementary Figures 2–4.
FIGURE 5 | GSKJ4 and A-485 treatments inhibit viability in T-ALL cell lines. Cell viability measurement by MTS assays (A,C) and protein expression levels of p27,
cleaved, and full-length form of PARP (C PARP and FL PARP, respectively) and c-Myc (B,D) in TALL-1, MOLT3, P12, DND41, and KOPTK1 cells treated for times
indicated in figure with 2µM of GSKJ4 (A,B) or with 5µM of A-485 (C,D). β-actin was used as loading control. Non-specific bands are indicated with asterisks. Cell
viability at each time point represents the mean of three biological replicates ± Standard Error of the Mean (S.E.M.); (n = 3) *P < 0.05, ***P < 0.001. Uncropped
western blots and additional exposures of films related to this figure are displayed in Supplementary Figures 6,7.
effects. To evaluate this hypothesis, we compared the number
of viable TALL-1 cells transiently transfected with an expression
vector encoding human c-Myc with their counterpart transfected
with the empty vector after 48 h of exposure to these agents.
Notably, expression of exogenous c-Myc partially rescued the
viability of Notch3-dependent TALL-1 cells exposed to GSKJ4
or A-485 (Figure 6C), suggesting that both treatments elicited
their biological effects at least in part by targeting c-Myc signal
via Notch inhibition.
DISCUSSION
During the last decades T-ALL cure rate has improved. However,
relapse and drug-resistance represent the most common causes
of treatment failure, and patients that experienced relapse
undergo very poor prognosis (36–38). A deep understanding
of the molecular mechanisms driving dysregulated expression
and malfunction of key oncogenes or onco-suppressors in T-
ALL could unveil novel potential therapeutic targets and lead to
refinement of current therapies.
Given the prominent role of Notch1 and Notch3 signaling in
physiological development of many tissues and in pathogenesis,
chemo-resistance and relapse of different human cancers,
including T-ALL, many efforts have been paid to unveil
molecular mechanisms priming their activation or sustaining the
strength and the activity of their signaling (1). However, less
attention is paid to the upstream mechanisms regulating Notch
receptors expression, particularly those involved in Notch3
transcriptional activation.
Nowadays, Notch3 is considered a direct Notch1
transcriptional target, as Notch3 expression is strictly combined
with -on and -off states of Notch1 signaling in T-ALL cell
lines (14, 15). Consistently, the expression of two Notches
correlates during thymocytes development starting from the
uncommitted CD34+CD1+ up to CD4+CD8+CD3- Double
Positive (DP) stage (39). However, over than these observations,
Notch1 is highly expressed in early thymocytes precursors
and in mature single positive thymocytes, whereas Notch3 is
preferentially highly expressed in CD4−CD8− double negative
(DN) thymocytes, particularly at the pre-TCR-dependent
checkpoint stage, before shutting down in DP cells (39, 40).
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FIGURE 6 | Enforced Notch/c-Myc axis partially shields from inhibitory effects of GSKJ4 and A-485 on T-ALL cell viability. Change in number of viable cells after 48 h
of exposure to 2µM GSKJ4 or to 5µM A-485 in DND41 cells transduced with the mICN1 or with the empty control retroviruses (A, upper panel), in DND41 cells
transiently transfected with hICN3 or with the empty vector (B, upper panel), and in TALL-1 cells transfected with c-Myc or with the control plasmid (C, upper panel).
Numbers of viable cells were calculated via trypan blue exclusion assay. Relative cell number reported in charts represents the mean of at least four biological
replicates normalized to cell number in DMSO-treated cells transduced or transfected with empty control ± Standard Error of the Mean (S.E.M.); *P < 0.05,
**P < 0.01. Western blot analysis by using antibodies against: Notch1 in mICN1 transduced DND41 cells (A, lower panel), Notch3 in hICN3 transfected DND41 cells
(B, lower panel) and c-Myc in TALL-1 cells transfected with the c-Myc expression vector (C, lower panel). β-actin was used as loading control. Non-specific bands are
indicated with asterisks. Uncropped western blots related to this figure are displayed in Supplementary Figure 8.
In addition, high Notch3 expression and activity have been
described in Notch1-lacking T-ALL patient-derived xenografts
and in the established T-ALL cell line TALL-1 characterized by
inactive Notch1 signaling (9).
Previous evidence suggested epigenetic machinery driving
NOTCH3 expression in different cell context. However, not much
is known yet about the specific histone modifiers writing or
erasing the chromatin status at NOTCH3 gene locus especially in
Notch1-lacking T-ALL subsets. Here we highlighted additional
mechanistic insights into Notch3 regulation, thus advancing the
understanding of distinct interplays/relationships between Notch
receptors and histones modifiers relevant to Notch3 oncogenic
activation in T-ALL. Supporting the previously described
common transcriptional activity byNotch1 andNotch3 receptors
(10), we revealed that NOTCH3 gene expression is sustained
by active Notch signaling in T-ALL cells irrespectively of the
specific Notch receptor involved. We found that Notch3, as well
as Notch1 signaling, activates NOTCH3 transcription through a
chromatin-modification-based mechanism by coordinating the
recruitment of JMJD3 and p300/CBP chromatin remodelers,
thus preserving H3K27 active epigenetic marks (Figures 7A,B).
Therefore, we propose that this mechanism of transcriptional
control may be a general Notch-dependent mechanism rather
than a Notch1-specific one, as previously suggested, at least in
some T-ALL contexts.
In addition, since Notch1 on/off states combined with
changes in NOTCH3 expression levels in Notch1-dependent
T-ALL cell lines MOLT3 and P12 and given that Notch3
activity strictly correlated with NOTCH1 expression in
Notch3-dependent TALL-1 cells, we hypothesized that the
reciprocal regulation by which Notch receptors modulate each
other’s transcriptional activity could represent a mechanism
by which either Notch self-sustains a positive-feedback
loop in T-ALL. Moreover, the expression of both receptors
and their target genes was decreased by GSKJ4 and A-485
treatment, therefore indicating JMJD3 and p300 as major
drivers of Notch receptors’ transcriptional activation and
activity (Figures 7C,D).
Although in the last decades several potential anti-Notch
approaches have been proposed (41, 42), to date, the most
explored class of Notch blocking agents, the gamma-secretase
inhibitors (GSIs), is not effective in all contexts and often causes
intestinal goblet cell metaplasia (43). Therefore, identification
of novel key factors and mechanisms sustaining growth in T-
ALL could drive the design of advanced therapeutic strategies
avoiding severe GSI-related side effects. In line with this aim,
we found that GSKJ4 treatment, as well as exposure to A-485,
suppressed the viability of human T-ALL cell lines by promoting
the accumulation of anti-proliferative factor p27 and related to
apoptosis cleaved form of PARP and by suppressing protein
levels of the oncogenic Notch target c-Myc (Figures 7C,D).
Notably, enforced expression of the active domain of both
Notch1 and Notch3 partially rescued DND41 cell lines from anti-
growth effects induced by GSKJ4 and A-485, thus indicating
that Notch inhibition is responsible, at least in part, of
the cell viability-inhibiting effect of both drugs. Subsequent
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FIGURE 7 | The histone modifiers JMJD3 and p300 sustain Notch signaling and cell viability in T-ALL. (A) Notch signaling trans-activation is primed by the binding
between a Notch receptor (N3R or N1R) and a ligand expressed on the surface of two neighboring cells. Ligand interaction allows two consecutive proteolytic
cleavages of the receptor by ADAM metalloproteases and by the gamma-secretase complex that releases the active Notch intracellular domain (N3ICD or N1ICD)
from the cell membrane leading to its nuclear translocation. In the nucleus, N3ICD or N1ICD associates with the DNA binding protein CBF1–Suppressor of
Hairless(SuH)–LAG1 (CSL) and assembles a multifactorial transcriptional complex including MAML1 complex (MAM) and p300 to promote Notch target gene
expression. By our study, we demonstrated that the binding of N3ICD, as well as N1ICD, to the regulatory region of NOTCH3, is strictly associated with high levels of
accumulation of the active chromatin marks H3K27ac and H3K4me3 on the NOTCH3 gene locus and combines with the co-recruitment of the histone modifiers p300
and JMJD3. Moreover, we found that the interplay between Notch and these histone modifiers is required to sustain NOTCH3 expression in T-ALL cells. (B) Indeed,
pharmacological inhibition of the last step of Notch signaling activation, by the gamma-secretase inhibitor DAPT, restrains the binding of JMJD3 and p300 to the
NOTCH3 gene, allows H3K27me3 accumulation and counteracts NOTCH3 expression. (C) Therefore, JMJD3 and p300 sustain the expression and the oncogenic
transcriptional activity of Notch3 and Notch1 receptors in T-ALL cells. (D) Accordingly, the pharmacological inhibition of their enzymatic activity by treatment with
GSKJ4 and A-485, respectively produced the following outcomes: (i) reduced NOTCH3 and NOTCH1 levels; (ii) decreased the expression of Notch target genes
DELTEX1 and c-MYC; (iii) promotes the accumulation of the cell cycle-regulator factors p27Kip1 and of the apoptosis-related cleaved form of PARP (C PARP); (ìv)
impairs viability in several T-ALL cell lines.
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investigations in TALL-1 cells indicated that biological effects
associated to GSKJ4 and A-485 might be mostly due to the
inhibition of the Notch/c-Myc regulatory axis, as both treatments
converged to c-Myc suppression and its enforced expression
preserved cells from the treatment-associated effects on T-
ALL cell viability. These last findings further indicate c-Myc
as a prominent mediator of Notch oncogenic function that is
consistent with the essential role of c-Myc in Notch1-driven
leukemia (5, 44, 45) and with its property to rescue T-ALL
cells from the anti-growth effects of Notch1 inhibition by GSI
treatment (6, 44).
Overall, our study supports previous researches indicating
GSKJ4 as a promising therapeutic agent in Notch1- and TAL1-
dependent T-ALL (19, 21), while laying the basis for extending
its potential use also to Notch3- and c-Myc- dependent T-
cell leukemia contexts. Besides, it suggests further investigation
on the targeting of p300/CBP by the A-485 compound as
an additional therapeutic option against T-cell hematopoietic
malignancies. Notably, efficacy and safety of these two epigenetic
drugs is supported by previous pre-clinical studies showing
that GSKJ4 and A-485 exerted anti-tumor activities in T-ALL
and prostate cancer mice models, respectively, without evident
adverse effects (19, 21, 35).
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